

## Synthesis, Biological and Pharmacological Activities of Some New Derivatives of 5-Aryl-1,3,4-thiadiazolidin-2-thiones

M. ARUNA DEVI and V.M. REDDY\*  
Medicinal Chemistry Research Laboratory  
Kakatiya University, Warangal-506 009, India

Two different S-(5-aryl-1,3,4-thiadiazol-2-yl)mercaptoacetic acids were synthesized from the respective 5-aryl-1,3,4-thiadiazolidin-2-thiones on reaction with chloroacetic acid. Each of these acids has been converted *in situ* into acid chloride using thionyl chloride and condensed with three different secondary amines *viz.*, dicyclohexylamine, morpholine and piperidine. The products obtained in each case were purified and characterized as the respective N,N-disubstituted S-(5-aryl-1,3,4-thiadiazol-2-yl)mercaptoacetamides. Alternatively the *in situ* acid chlorides were allowed to react with 2-methoxyethanol and 2-ethoxyethanol. These products have been purified and characterized as the respective esters, *i.e.*, 2-alkoxyethyl S-(5-aryl-1,3,4-thiadiazol-2-yl)mercaptoacetates. Similarly, the acid chlorides *in situ* have been also allowed to react with two different N-substituted aminoethanols and the products were characterized as the respective 2-N,N-substituted aminoethyl S-(5-aryl-1,3,4-thiadiazole-2-yl)-mercaptoacetates. All the three types of new derivatives of 5-aryl-1,3,4-thiadiazolidin-2-thiones were assayed for their antibacterial, antifungal, antihistaminic and anticholinergic activities by standard methods.

**Key Words:** 5-Aryl-1,3,4-thiazolidin-2-thiones, Secondary amines, Antimicrobial activity, Anticholinergic activity, Antihistaminic activity.

### INTRODUCTION

1,3,4-Thiadiazole system is known for its wide variety of biological and pharmacological actions such as: antimicrobial<sup>1</sup> (mostly antifungal), insecticidal<sup>2</sup>, anticholinergic<sup>3</sup>, antihypertensive<sup>4</sup>, CNS depressant<sup>5</sup>, anti-inflammatory<sup>6</sup>, hypoglycemic<sup>7</sup>, antihelminthic<sup>8</sup>, anticancer<sup>9</sup>, *etc.* Though the literature presents several fused and bridged macromolecular thiadiazole, it appears that less attention has been made on simple thiadiazole derivatives. Therefore, in this paper, the synthesis of some new functional derivatives of 1,3,4-thiazolidin-2-thiones are reported and screened them for their antibacterial, antifungal, anticholinergic and H<sub>1</sub>-antihistaminic activities by standard methods.

## EXPERIMENTAL

Melting points were determined in open capillaries using Cintex melting point apparatus and are uncorrected. The IR spectra of the compounds were recorded in Perkin-Elmer infracord-283 spectrophotometer as KBr pellets, <sup>1</sup>H NMR spectra as OMEGA-500 MHz spectrometer using TMS as an internal standard and mass spectra on a FINNIGAN MAT-90 in the EI mode and by the direct inlet method.

Benzoic acid (a) and 4-nitrobenzoic acid (b) were converted into their corresponding acid hydrazides by known procedure and the acid hydrazide was reacted with ammonia and carbondisulphide to obtain the corresponding 5-aryl-1,3,4-thiadiazolidin-2-thione (**Ia** and **b**) purified by recrystallization and identified by their literature<sup>10,11</sup> melting points and other data.

**Synthesis of S-(5-aryl-1,3,4-thiadiazol-2-yl)mercaptoacetic acids (IIa and b):** To a solution of appropriate 5-aryl-1,3,4-thiadiazolin-2-thione (**I**; 0.01 mol) in alcoholic sodium hydroxide (4 %; 10 mL) chloroacetic acid (0.012 mol) was added and heated under reflux for about 4 h. The reaction mixture was cooled, filtered, if necessary and the clear, cold solution was neutralized with dilute hydrochloric acid. The product thus separated was filtered, washed with cold water, dried and purified.

Adopting the above specified procedure the following two different substituted mercepto acetic acids were prepared and characterized:


**S-(5-Phenyl-1,3,4-thiadiazol-2-yl)mercaptoacetic acid (IIa; Ar = -C<sub>6</sub>H<sub>5</sub>):** Purified by recrystallization from methanol to obtain a colourless crystalline solid, m.p. 154 °C. Yield : 65 %; [Found: C, 47.55; H, 3.14; N, 11.05; m.f. C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> requires: C, 47.61; H, 3.17; N, 11.11, respectively].

**S-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl)mercaptoacetic acid (IIb; Ar = 4-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>):** It was purified by recrystallization from methanol to yield an yellow crystalline solid m.p. 150 °C, yield: 68 % [Found: C, 40.20; H, 3.35; N, 14.65; m.f. C<sub>10</sub>H<sub>4</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> requires: C, 40.26; H, 3.40; N, 14.09].

**Synthesis of N,N-disubstituted S-(5-aryl-1,3,4-thiadiazol-2-yl)-mercaptoacetamides (IV):** The mercaptoacetic acid (**II**; 0.01 mol) was taken into a dry flask and thionyl chloride (0.015 mol) was added. It was then heated under reflux for 0.5 h on a hot water-bath under anhydrous conditions, using calcium chloride guard tube. After the fumes of excess thionyl chloride were ceased off, an appropriate secondary amine was added (0.012 mol) followed by pyridine (2 mL). The reaction mixture was heated under reflux for further 6 h. It was cooled and poured onto crushed ice (~ 100 g) while stirring with a glass rod. The product separated was filtered under suction, washed thoroughly with small portions of cold water and purified.

**Synthesis of 2-dialkylaminoethyl S-(5-aryl-1,3,4-thiadiazol-2-yl)-mercaptoacetates (V):** To the acid chloride (*in situ*) prepared as above an appropriate 2-dialkylaminoethanol (0.012 mol) and pyridine (2 mL) were added. The reaction mixture was heated under reflux for 6 h. It was then cooled and poured onto crushed ice (~100 g) while stirring with a glass rod. The product thus separated was filtered under suction, washed thoroughly with small portions of cold water, dried and purified.

**Synthesis of 2-alkoxyethyl S-(5-aryl-1,3,4-thiadiazol-2-yl)mercaptoacetates (VI):** To the acid chlorides (II; 0.010 mol) an appropriate 2-alkoxyethanol (0.012 mol) and pyridine (2 mL) were added. The reaction mixture was heated under reflux for 6 h. The reaction mixture was cooled and poured onto crushed ice (~100 g) while stirring. The product obtained was filtered under suction, washed with cold water, dried and purified (**Scheme-I**). The characterization data of compounds IV, V and VI are presented in Table-1.



Scheme-I

TABLE-1  
CHARACTERIZATION DATA OF DERIVATIVES OF  
5-ARYL-1,3,4-THIADIAZOLIN-2-THIONES

Compd.	Nature of the substituents		m.p. (°C) / Yield (%)	Elemental analyses (%): Calcd. (Found)		
	Ar	N R <sup>1</sup> R <sup>2</sup> /R <sup>3</sup> (IV)		C	H	N
<b>IVa</b>	C <sub>6</sub> H <sub>5</sub>	Dicyclohexylamino	121 (70)	63.55 (63.61)	6.90 (6.98)	10.08 (10.12)
<b>IVb</b>	C <sub>6</sub> H <sub>5</sub>	Morpholino	132 (68)	52.30 (52.33)	4.60 (4.67)	13.00 (13.08)
<b>IVc</b>	C <sub>6</sub> H <sub>5</sub>	Piperidino	140 (60)	56.39 (56.42)	5.30 (5.32)	13.10 (13.16)
<b>IVd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dicyclohexylamino	242 (80)	57.20 (57.26)	6.00 (6.07)	12.10 (12.14)
<b>IVe</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Morpholino	130 (78)	45.72 (45.77)	3.78 (3.81)	15.20 (15.25)
<b>IVf</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Piperidino	188 (70)	49.28 (49.31)	4.34 (4.38)	15.30 (15.34)
<b>Va</b>	C <sub>6</sub> H <sub>5</sub>	Diethylamino	275 (58)	54.65 (54.70)	5.95 (5.98)	11.92 (11.96)
<b>Vb</b>	C <sub>6</sub> H <sub>5</sub>	Dimethylamino	256 (60)	51.08 (52.01)	5.25 (5.26)	12.95 (13.00)
<b>Vc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Diethylamino	252 (55)	48.30 (48.36)	5.00 (5.03)	13.80 (14.10)
<b>Vd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dimethylamino	220 (65)	45.45 (45.52)	4.30 (4.33)	15.10 (15.17)
<b>VIa</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	172 (82)	51.80 (51.85)	4.90 (4.93)	8.60 (8.64)
<b>VIb</b>	C <sub>6</sub> H <sub>5</sub>	CH <sub>3</sub>	135 (75)	50.28 (50.32)	4.45 (4.51)	9.00 (9.03)
<b>VIc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	C <sub>2</sub> H <sub>5</sub>	273 (78)	45.35 (45.40)	4.00 (4.05)	11.25 (11.35)
<b>VIId</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	170 (80)	43.79 (43.82)	3.60 (3.65)	11.74 (11.79)

\*Purification of compounds has been effected by recrystallization from appropriate solvents, viz.,

\*Characterization data of a representative compound: **IVb**: IR (KBr,  $\nu_{\max}$ , cm<sup>-1</sup>): 1720 (amide C=O), 1625 (thiadiazole C=N) 1610 (aromatic C=C); <sup>1</sup>H NMR (CDCl<sub>3</sub>, ppm) peaks at 2.92 [t, 4H, O(CH<sub>2</sub>)<sub>3</sub>, morpholine], 3.68 [t, 9H, -CO-N(CH<sub>2</sub>)<sub>2</sub> morpholine], 3.90 (t, 2H, -S-CH<sub>2</sub>-CO) and 6.72-7.88 (m, 5H, aromatic). **Vb**: IR (KBr,  $\nu_{\max}$ , cm<sup>-1</sup>): 1725 (C=O, ester), 1625 (C=N, heteryl) 1605 (C=C, aromatic). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>,  $\delta$  ppm): 3.68 (s, 6H, -NMe<sub>2</sub>), 4.10 (t, 2H, -N-CH<sub>2</sub>), 4.40 (t, 2H, -CO-O-CH<sub>2</sub>), 4.80 (s, 2H, -S-CH<sub>2</sub>-CO). **VIa**: IR (KBr,  $\nu_{\max}$ , cm<sup>-1</sup>): 1720, 1620, 1605 for C=O, C=N and C=C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>,  $\delta$ , ppm): 2.30 (t, 3H, -O-CH<sub>2</sub>-CH<sub>3</sub>), 2.55 (q, 2H, -O-CH<sub>2</sub>-CH<sub>3</sub>), 3.85 (t, 2H, -CO-O-CH<sub>2</sub>-CH<sub>2</sub>-O).

**Biological/Pharmacological activities**<sup>12,13</sup>: Male albino mice fasted for 24 h, administered all test compounds suspended in sodium CMC intra-peritoneally in doses of 50 mg to 500 mg/kg (b.w.). The animals were observed for 48 h from the time of administration of test compounds to record the mortality.

**Acute toxicity and gross behavioural studies:** All the compounds tested for acute toxicities were also observed for gross behaviour changes continuously for 3 h starting from the administration of the compounds and for 48 h, intermittently and compared with that of control groups of mice.

**Antibacterial activity:** The antibacterial activity of the test compounds was assayed, systematically against five different strains of bacteria: *B. subtilis*, *B. mycooides*, *E. coli*, *P. aeruginosa* and *P. vulgaris* (two gram positive and three gram-negative) by agar diffusion method<sup>14</sup> benzyl penicillin and streptomycin as standards.

**Antifungal activity<sup>14</sup>:** All the compounds were also tested for their antifungal activity by the cup-plate method and the fungi employed were for *F. oxysporum* and *C. lunata*. Clotrimazole employed as the standard comparison.

**Antihistaminic activity:** The test compounds were screened for their antihistaminic activity by using isolated Guinea-pig ileum method<sup>15</sup> at concentration employed as a reference for comparison.

**Anticholinergic activity:** The anti-cholinergic activity of the compounds were screened by using rat intestine, following the standard procedure.

## RESULTS AND DISCUSSION

**Acute toxicity for gross behavioural studies:** All the test compounds upto an oral dose of 250 mg/kg (bw) were found to be safe. No significant changes were recorded in the gross behavioural studies of the compounds.

**Antibacterial activity:** It is interesting to note that the present compounds and relatively less effective against both the gram (+)ve bacteria and specifically more effective against the gram (-)ve. Even amongst the three strains of gram (-)ve bacteria, the compounds were significantly potent against *Pseudomonas aeruginosa* than the other two. But, however, their potency was not at all comparable with that of the standard, since the compounds could exhibit antibacterial activity only at considerably higher concentration in comparison to that of the standard (Table-2).

**Antifungal activity:** Table-3 revealed that new derivatives of thiadiazole are relatively more effective towards *C. lunata* when compared with *F. oxysporum*. Compound **IVd**, **IVe**, **VIa** and **VIb** were found to exhibit reasonable activity. But however, the antifungal activity of these compounds is not comparable with that of the standard employed.

**H<sub>1</sub>-Antihistaminic activity:** As can be observed from Table-4, the compound **VIc**, with a 4-nitrophenyl and ethyl groups is relatively more potent amongst all the present. Compounds with IC<sub>50</sub>: 508 µg and the second in order being **IVd** with 4-nitrophenyl and a dicyclohexylamino groups with IC<sub>50</sub>: 570 µg. But, however, their potency is not at all comparable with the standard.

TABLE-2  
ANTIBACTERIAL ACTIVITY DATA OF NEW DERIVATIVES OF  
5-ARYL-1,3,4-THIADIAZOLIN-2-THIONES

Compd.	Substituents		Zone of inhibition (mm)				
	Ar	N R <sup>1</sup> R <sup>2</sup> /R <sup>3</sup> (IV)	BS	BM	EC	PA	PV
<b>IVa</b>	C <sub>6</sub> H <sub>5</sub>	Dicyclohexylamino	17	8	10	15	14
<b>IVb</b>	C <sub>6</sub> H <sub>5</sub>	Morpolino	12	7	12	24	15
<b>IVc</b>	C <sub>6</sub> H <sub>5</sub>	Piperidino	8	6	13	29	16
<b>IVd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dicyclohexylamino	15	9	15	35	16
<b>IVe</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Morpolino	15	5	8	36	14
<b>IVf</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Piperidino	16	7	10	29	17
<b>Va</b>	C <sub>6</sub> H <sub>5</sub>	Diethylamino	10	6	14	31	11
<b>Vb</b>	C <sub>6</sub> H <sub>5</sub>	Dimethylamino	9	5	14	30	10
<b>Vc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Diethylamino	12	6	16	36	15
<b>Vd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dimethylamino	10	6	8	38	14
<b>VIa</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	10	5	16	31	13
<b>VIb</b>	C <sub>6</sub> H <sub>5</sub>	CH <sub>3</sub>	9	4	15	30	11
<b>VIc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	C <sub>2</sub> H <sub>5</sub>	11	5	16	34	10
<b>VI d</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	12	4	16	35	15
Gram(+ve)	Benzylpenicillin (Standard)		30	31	–	–	–
Gram(-ve)	Streptomycin (Standard)		–	–	40	42	43
	Control		–	–	–	–	–

BS = *B. subtilis*, BM = *B. mycoides*, EC = *E. coli*, PA = *P. auroginosa*, PV = *P. vulgaris*  
Test compound 1000 µg/mL concentration; Standard 100 µg/mL concentration.

TABLE-3  
ANTIFUNGAL ACTIVITY DATA OF NEW DERIVATIVES OF  
5-ARYL-1,3,4-THIADIAZOLIN-2-THIONES

Compd.	Substituents		Zone of inhibition (mm)	
	Ar	N R <sup>1</sup> R <sup>2</sup> / R <sup>3</sup>	<i>F. oxysporum</i>	<i>C. lunata</i>
<b>IVa</b>	C <sub>6</sub> H <sub>5</sub>	Dicyclohexylamino	13	20
<b>IVb</b>	C <sub>6</sub> H <sub>5</sub>	Morpolino	15	25
<b>IVc</b>	C <sub>6</sub> H <sub>5</sub>	Piperidino	13	26
<b>IVd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dicyclohexylamino	15	33
<b>IVe</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Morpolino	13	33
<b>IVf</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Piperidino	14	24
<b>Va</b>	C <sub>6</sub> H <sub>5</sub>	Diethylamino	11	29
<b>Vb</b>	C <sub>6</sub> H <sub>5</sub>	Dimethylamino	19	27
<b>Vc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Diethylamino	16	18
<b>Vd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dimethylamino	18	20
<b>VIa</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	17	31
<b>VIb</b>	C <sub>6</sub> H <sub>5</sub>	CH <sub>3</sub>	–	32
<b>VIc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	C <sub>2</sub> H <sub>5</sub>	20	28
<b>VI d</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	–	30
Clotrimazole (standard) (1 mg/mL conc. in DMF)			20	39

TABLE-4  
ANTI-HISTAMINIC ACTIVITY DATA OF NEW DERIVATIVES OF  
5-ARYL-1,3,4-THIADIAZOLIN-2-THIONES

Compd.	Substituents		Dose of which 50 % inhibition is observed IC <sub>50</sub> (µg)
	Ar	N R <sup>1</sup> R <sup>2</sup>	
<b>IVa</b>	C <sub>6</sub> H <sub>5</sub>	Dicyclohexylamino	602.66
<b>IVb</b>	C <sub>6</sub> H <sub>5</sub>	Morpolino	895.63
<b>IVc</b>	C <sub>6</sub> H <sub>5</sub>	Piperidino	899.49
<b>IVd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dicyclohexylamino	570.65
<b>IVe</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Morpolino	905.37
<b>IVf</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Piperidino	892.85
<b>Va</b>	C <sub>6</sub> H <sub>5</sub>	Diethylamino	750.05
<b>Vb</b>	C <sub>6</sub> H <sub>5</sub>	Dimethylamino	764.26
<b>Vc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Diethylamino	946.00
<b>Vd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dimethylamino	781.25
<b>VIa</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	777.60
<b>VIb</b>	C <sub>6</sub> H <sub>5</sub>	CH <sub>3</sub>	927.41
<b>VIc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	C <sub>2</sub> H <sub>5</sub>	508.13
<b>VIId</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	774.64
	Avil standard		480.00

**Anticholinergic activity:** The anticholinergic potency of new derivatives is not comparable with that of the standard atropine employed in the investigation (Table-5). They could exhibit the activity only at quite higher dose. But, amongst all the present compounds, compound **VIb** with a 4-nitrophenyl and ethyl substituent was found to be relatively more potent with an IC<sub>50</sub> value: 141 µg.

TABLE-5  
ANTICHOLINERGIC ACTIVITY DATA OF NEW DERIVATIVES OF  
5-ARYL-1,3,4-THIADIAZOLIN-2-THIONES

Compd.	Substituents		Dose of which 50 % inhibition is observed IC <sub>50</sub> (µg)
	Ar	N R <sup>1</sup> R <sup>2</sup>	
<b>IVa</b>	C <sub>6</sub> H <sub>5</sub>	Dicyclohexylamino	142.45
<b>IVb</b>	C <sub>6</sub> H <sub>5</sub>	Morpolino	166.40
<b>IVc</b>	C <sub>6</sub> H <sub>5</sub>	Piperidino	142.04
<b>IVd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dicyclohexylamino	135.86
<b>IVe</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Morpolino	173.61
<b>IVf</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Piperidino	141.12
<b>Va</b>	C <sub>6</sub> H <sub>5</sub>	Diethylamino	169.37
<b>Vb</b>	C <sub>6</sub> H <sub>5</sub>	Dimethylamino	184.85
<b>Vc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Diethylamino	161.49
<b>Vd</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Dimethylamino	127.98
<b>VIa</b>	C <sub>6</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	141.75
<b>VIb</b>	C <sub>6</sub> H <sub>5</sub>	CH <sub>3</sub>	129.43
<b>VIc</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	C <sub>2</sub> H <sub>5</sub>	130.20
<b>VIId</b>	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CH <sub>3</sub>	176.71
	Standard	Atropine (1 mg/mL conc.)	30.00

### ACKNOWLEDGEMENTS

The authors thank the authorities of University College of Pharmaceutical Sciences, Kakatiya University, Warangal for providing the facilities. One of the authors, M. Aruna Devi is grateful to the University Grants Commission, New Delhi for the fellowship.

### REFERENCES

1. S. Giri and H. Singh, *J. Indian Chem. Soc.*, **49**, 175 (1972).
2. A.K. Sengupta, K.C. Agarwal and M. Mushtaq, *J. Indian Chem. Soc.*, **54**, 1961 (1977).
3. A.K.S. Gupta and H.K. Mishra, *J. Pharm. Sci.*, **69**, 749 (1980).
4. R. Gupta, Satyapaul, A.K. Gupta and P.L. Kachroo, *Indian J. Chem.*, **37B**, 498 (1998).
5. S.S. Tiwari and R.K. Raostogi, *J. Indian Chem. Soc.*, **55**, 477 (1978).
6. D.H. Boschelli, D.T. Connar and D.A. Bornemeir, *J. Med. Chem.*, **36**, 1803 (1993).
7. M.I. Hussain and M.R. Jamali, *Indian J. Chem.*, **27B**, 43 (1988).
8. A.K. Padhy, V.C. Nug and C.S. Panda, *Indian J. Chem.*, **38B**, 998 (1999).
9. C. Parkanyi, H.L. Yuan, B.H.C. Stromberg and A. Evenzahar, *J. Heterocycl. Chem.*, **29**, 749 (1992).
10. G.A. Pearse, *Chem. Abstr.*, **56**, 141621 (1962).
11. M. Kidwai, K.R. Bhushan, P. Kumar and R. Kumar, *Monatsh Chemie*, **128**, 1291 (1997).
12. J.T. Litchfield and F. Wilcoxin, *J. Pharmacol. Exptl. Therap.*, **96**, 99 (1949).
13. A.T. Robert, *Screening Methods in Pharmacology*, Academic Press, New York Vol. 2, p. 214 (1971).
14. *British Pharmacopoeia* (Pharmaceutical Press), London, p. 796 (1953).
15. J.J. Reuse, *Brit. J. Pharmacol.*, **3**, 174 (1948).

(Received: 28 June 2007; Accepted: 16 June 2008) AJC-6619

**21ST INTERNATIONAL SYMPOSIUM ON CHIRALITY**

**12 — 15 JUNE 2009**

**BECKENRIDGE (COLORADO), USA**

Contact:

E-mail: janetbarr@aol.com